Cannabis Science Receives U.S. Federal Government CAGE/NCAGE Code Certification
SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce that the Company has received its CAGE/NCAGE Code: 5FZM9 certification through Central Contracting Registration (CCR). Cannabis Science is now listed along with all U.S., and NATO companies with a CAGE/NCAGE Code. The CCR is the primary vendor database for the U.S. Federal Government and is used as a government tool for the Department of Homeland Security, Department of Defense, NATO and NASA Agencies. Having this information immediately available allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government initiatives, including research & development projects, particular supply needs, up to a pandemic alert requirement or other emergency requirements.
Cannabis Science Inc. President and CEO, Steve Kubby comments on the Companyâ€™s receipt of their CAGE/NCAGE Code, "With this CAGE/NCAGE Code assignment Cannabis Science Inc. is certified to work as a prime contractor for the U.S. Government. This government registration and validation of our services is very important to Cannabis Science Inc., as it publicly validates our collective experience and allows us to bid on and receive U.S. Government contracts on any level. We are now listed in both the Defense Logistics Information Service (DLIS) a lookup service of the Commercial and Government Entity CAGE/NCAGE Code system via the World Wide Web."
Cannabis Science Inc. has specifically received U.S. Federal Government Classification for North American Industry Classification System (NAICS) 541711 - Research and Development in Biotechnology, 621511 - Medical Laboratories, 624230 - Emergency and Other Relief Services. The Company has also received U.S. Government Classification for Standard Industrial Classification (SIC) for 8731 - Commercial Physical and Biological Research, enabling it to receive government notifications and requests for services under these classifications.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.